- Title: A descriptive study of the impact of diseases control and prevention on the epidemics 1
- 2 dynamics and clinical features of SARS-CoV-2 outbreak in Shanghai, lessons learned for
- 3 metropolis epidemics prevention.
- 4
- 5

Hongzhou Lu<sup>2</sup>, Jingwen Ai<sup>1</sup>, Yinzhong Shen<sup>2</sup>, Yang Li<sup>1</sup>, Tao Li<sup>2</sup>, Xian Zhou<sup>1</sup>, Haocheng 6 7 Zhang<sup>1</sup>, Qiran Zhang<sup>1</sup>, Yun Ling<sup>2</sup>, Sheng Wang<sup>3</sup>, Hongping Qu<sup>4</sup>, Yuan Gao<sup>6</sup>, Yingchuan Li<sup>7</sup>, Kanglong Yu<sup>8</sup>, Duming Zhu<sup>5</sup>, Hecheng Zhu<sup>9</sup>, Rui Tian<sup>8</sup>, Mei Zeng<sup>10</sup>, Qiang Li<sup>11</sup>, Yuanlin 8 Song<sup>5</sup>, Xiangyang Li<sup>12</sup>, Jinfu Xu<sup>13</sup>, Jie Xu<sup>14</sup>, Engiang Mao<sup>4</sup>, Bijie Hu<sup>5</sup>, Xin Li<sup>5</sup>, Lei Zhu<sup>5</sup>, 9 Wenhong Zhang<sup>1</sup> on behalf of the Shanghai Clinical Treatment Expert Group for SARS-10 11 CoV-2 12

- Hongzhou Lu, Jingwen Ai, Yinzhong Shen, Yang Li contributed equally to this manuscript 13
- 15 Correspondence:
- Wenhong Zhang, Department of Infectious Diseases, Fudan University, Shanghai 200040. 16
- 17 Mailing address: 12 Wulumugi Zhong Road, Shanghai, China. Tel: +86-21-52888123. Fax: +86-
- 18 21-62489015. Email: wenhongzhang hs@126.com.
- 19

14

#### 20 Affiliations:

- 21 Department of infectious disease, Huashan Hospital of Fudan University, Shanghai, China 1.
- 2. Shanghai Public Health Clinical Center, Fudan University, Shanghai, China 22
- 3. Shanghai Tenth People's Hospital of Tongji University, Shanghai, China 23
- 24 4. Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- 25 5. Zhongshan Hospital of Fudan University, Shanghai, China
- 6. Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China 26
- 7. Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, 27 28 Shanghai, China
- 29 8. Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 30 Shanghai, China
- 31 9. Department of Critical Care Medicine, Huashan Hospital of Fudan University, Shanghai, 32 China
- 10. Children's Hospital of Fudan University, Shanghai, China 33
- 11. Shanghai East Hospital of Tongji University, Shanghai, China 34
- 12. Huadong Hospital of Fudan University, Shanghai, China 35
- 13. Shanghai Pulmonary Hospital of Tongji University, Shanghai, China 36
- 37 14. Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine,

Shanghai, China 38

39 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

40 41	Abstract
42	<b>Objective</b> To describe and evaluate the impact of diseases control and prevention on
43	epidemics dynamics and clinical features of SARS-CoV-2 outbreak in Shanghai.
44	
45	<b>Design</b> A retrospective descriptive study
46	
47	Setting China
48	•
49	<b>Participants</b> Epidemiology information was collected from publicly accessible database.
50	265 patients admitted to Shanghai Public Health Center with confirmed COVID-19 were
51	enrolled for clinical features analysis.
52	
53	Main outcome measure Prevention and control measures taken by Shanghai government.
54	epidemiological, demographic, clinical, laboratory and radiology data were collected.
55	Weibull distribution, Chi-square test, Fisher's exact test, t test or Mann-Whitney U test were
56	used in statistical analysis.
57	,
58	Results COVID-19 transmission rate within Shanghai had reduced over 99% than
59	previous speculated, and the exponential growth has been stopped so far. Epidemic was
60	characterized by the first stage mainly composed of imported cases and the second stage
61	where >50% of cases were local. The incubation period was 6.4 (95% CI 5.3 to 7.6) days
62	and the mean onset-admission interval was 5.5 days (95% CI, 5.1 to 5.9). Median time for
63	COVID-19 progressed to severe diseases were 8.5 days (IQR: 4.8-11.0 days). By February
64	11 <sup>th</sup> , proportion of patients being mild, moderate, severe and critically ill were 1.9%(5/265),
65	89.8%(238/265), 3.8%(10/265), 4.5%(12/265), respectively; 47 people in our cohort were
66	discharged, and 1 patient died.
67	
68	<b>Conclusion</b> Strict controlling of the transmission rate at the early stage of an epidemic in
69	metropolis can quickly prohibit the spread of the diseases. Controlling local clusters is the
70	key to prevent outbreaks from imported cases. Most COVID-19 severe cases progressed
71	within 14 days of disease onset. Multiple systemic laboratory abnormalities had been
72	observed before significant respiratory dysfunction.
73	
74	Keyword COVID-19, SARS-CoV-2, epidemics dynamics, diseases control, clinical
75	features
76	
77	Introduction
78	Since December 2019, a novel coronavirus, later named by WHO as SARS-CoV-2,
79	emerged in Wuhan, China [1-3] and rapidly spread throughout Hubei province, with
80	clustered cases reported globally [4-5]. Until February 19th 2020, the total reported

81 confirmed corona virus disease 2019 (COVID-19) cases have reached more than 72,000 82 within mainland China, and 888 cases in other 25 countries globally and the increasing 83 number of cases and widening geographical spread have raised concerns 84 internationally[6]. Up until now, multiple studies have described the clinical characteristics of the COVID-19, including fever, fatigue, cough etc. Various researches reported intensive 85 care unit (ICU) admission rate between 19.1% to 32%[7-9], but this data mainly came from 86 87 Hubei regions, and it might be biased towards detecting severe cases at the beginning of the epidemic. Thus, clinical features from regions outside Hubei can further assist the 88 89 understanding of the disease's epidemiological and clinical characteristics. Shanghai reported its first case of SARS-CoV-2 infection in January 20th 2020, and the total 90 confirmed cases have reached to 333 cases by February 19th. As one of the global 91 92 metropolis, Shanghai faces a relatively higher epidemics danger due to the substantial 93 population mobility, and the risk is even doubled as Chunyun(a huge population flows during the Spring Festival) collided with the epidemics. During this outbreak, Shanghai has 94 95 issued a number of strict measures to lower the transmissibility, including the shutdown of 96 all large entertainment venue, reducing passenger flow and very strong social propaganda. 97 Therefore, whether the Shanghai model has an impact on the epidemics dynamics and 98 disease control is an important reference to the other metropolises around the world. In 99 our study, we aimed to retrospectively describe the impact of diseases control on epidemics 100 dynamics and clinical features of SARS-CoV-2 outbreak in Shanghai, and to provide 101 valuable experience for other metropolises around the world.

### 103 Methods

#### 104 Study design and participants

105 This is a retrospective, single-center cohort study, recruiting all patients admitted to 106 Shanghai Public Health Center (SHPHC) diagnosed with coronavirus disease 2019 107 (COVID 2019) according to WHO interim guidance before Feb 7<sup>th</sup>, 2020. According to the 108 arrangement of government, almost all adult patients from whole Shanghai were admitted 109 to SHPHC once coronavirus disease 2019(COVID-19) was confirmed by real-time PCR. 110 The study was approved by SHPHC ethics committee and oral consent was obtained from 111 patients.

112

113 All patients admitted to Shanghai Public Health Center diagnosed with coronavirus disease

114 COVID-19 according to WHO interim guidance were enrolled in this study [10]. Two cohorts

115 were generated in this study, mild-moderate cohort and severe-critically ill cohort. All

116 COVID-19 patients are classified as mild to critically ill cases at admission, according to

117 COVID-19 Guidelines (the fifth version) made by National Health Commission of the

118 People's Republic of China. The classifying criteria was as follows:

119 Mild: Presenting mild symptoms and normal radiology manifestation in both lungs.

120 Moderate (typical): Presenting typical symptoms (fever, cough and other respiratory

121 symptoms) and radiology manifestation suggesting pneumonia.

122 Severe: Presenting any one of the followings:

123 1) Respiratory distress, respiratory rates ≥30 per minute;

124 2) Pulse oxygen saturation ≤93% on room air

- 125 3) Oxygenation Index (PaO2/FiO2) ≤300mmHg
- 126 Critically ill: Presenting any one of the followings
- 127 1) Respiratory failure where invasive ventilation is necessary
- 128 2) Signs of shock (circulatory failure)
- 3) Failure of any other organ where ICU care is necessary

130

### 131 Data Collection

132 The cumulative numbers of confirmed and suspected cases were collected from Shanghai

133 CDC, which were updated daily and publicly accessible. We obtained epidemiological,

demographic, clinical, laboratory and radiology data from patients' medical records. The

135 data were reviewed by a trained team of physicians. Information recorded included

demographic data, medical history, exposure history, comorbidities, symptoms, laboratory

137 findings at baseline and chest x-ray or computed tomographic (CT) scans. The date of

138 disease onset was defined as the day when the symptom was noticed.

139

#### 140 Statistical analysis

The incubation period distribution (i.e., the time delay from suspected contact to illness onset), and the onset-to-admission distribution was estimated by fitting a Weibull distribution to data on suspected exposure and onset dates in a subset of cases with detailed information available. Categorical variables were described as frequencies and percentages, and compared by Chi-square test or Fisher's exact test between two cohorts. Continuous variables were described as median and interguartile range (IQR) values.

147	Means for continuous variables were compared using independent group t-tests when the
148	data were normally distributed; otherwise, the Mann-Whitney test was used. For
149	comparisons, a 2-sided $\alpha$ of less than 0.05 was considered statistically significant. Results
150	of laboratory tests were also standardized and arranged by unsupervised hierarchical
151	clustering to identify the similarities, differences and characteristics, with Euclidean
152	distance measure and average linkage between groups methods. Statistical analyses were
153	performed using SPSS (Statistical Package for the Social Sciences) version 22.0 software
154	(SPSS Inc) and R software. Analyses of the incubation period, extensive predictive
155	analysis were performed with the use of MATLAB software (R2016b).

156

157 **Results** 

#### 158 Epidemiological analysis

As of February, 19th 2020, a total number of 72,531 confirmed COVID-19 cases have been 159 reported according to reports from 31 provinces (autonomous regions, municipalities) and 160 161 the Xinjiang Production and Construction Corps in mainland China. However, the number of newly increased cases, especially in regions outside Hubei provinces, has gradually 162 decreased since February 5<sup>th</sup> with the peak value of 3887. The same decreased trend can 163 be seen in the newly increased cases in Shanghai, with continuous declined growth rate 164 observed since February 4<sup>th</sup>. The total confirmed cases number of COVID-19 cases was 165 333 as of February 19<sup>th</sup> 2020, of which the percentage of COVID-19 cases without travel 166 history to Hubei province gradually surpassed 50%, according to the official report (Figure 167 1-A). The increased trend of cases without travel history to Hubei Provence and the 168

169 confirmed 45 clusters cases in Shanghai implied that the second-generation cases in 170 Shanghai had appeared gradually. In our study, the earliest symptom onset of all confirmed 171 patients can be traced back to January 6<sup>th</sup> 2020. The development of the epidemic followed 172 an exponential growth and a decline in newly reported cases (Figure 2).

The study examined data on suspected exposures among all 265 laboratoryconfirmed cases with detailed, 37 of whom had credible information on contacts to calculate the incubation period distribution. The mean incubation period is 6.4 days (95% CI 5.3 to 7.6) and the 5th and 95th percentile of the distribution was 0.97 and 13.10, respectively (Figure 3-A). The mean onset-admission interval was 5.5 days (95% CI, 5.1 to 5.9, SD 3.5). The 5th and 95th percentile of the distribution was 1 and 11.99, respectively (Figure 3-B).

180 We performed an extensive analysis to February 9<sup>th</sup> 2020 using the previously reported predictive parameterized transmission models in Shanghai and compared with 181 the actual reported confirmed cases [11-12]. The previous predictive model was based on 182 183 the hypothesis that no particular effective measures had been taken around the world and 184 the transmission among population had not been controlled. Our result showed that the transmission rate within Shanghai had all decreased more than 95% than previously 185 186 speculated, suggesting that the prevention and control interventions taken by Shanghai are of great impact on the overall control of the diseases during the current disease stage 187 (Figure 1-B). 188

189

#### 190 Baseline clinical features

191	220 (90.9%) patients had fever before admission. Nearly half of patients were presented
192	with pneumonia symptoms including cough (49.4%), expectoration (23.0%), chest pain
193	(2.3%). Other common symptoms included fatigue (25.3%), inappetences (11.7%),
194	headache (9.8%), myalgia (8.7%). Only 6.4% patients had diarrhea. Most symptom profile
195	were comparable between mild-moderate patients (N=243) and severe-critically ill patients
196	(N=22) while dyspnea occurred in a significantly higher proportion of severe or critical ill
197	patients (1/237 vs. 4/22, p<0.001). Eleven patients were asymptomatic on admission
198	(Table 1).

All patients underwent chest X-ray or CT at admission (Table 2). 202 (76.2%) patients showed bilateral pneumonia while 51 (19.2%) patients showed unilateral pneumonia, and 9 (3.4%) patients showed almost no abnormalities. The most common abnormalities were multiple ground-glass opacities. All asymptomatic patients had findings that consistent with pneumonia.

204 On admission, 120 (45.3%) and 39 (14.7%) patients had lymphopenia and leukopenia respectively (Table 2). Most patients had normal levels of hemoglobin and platelets (92.5% 205 and 82.0%, respectively). Elevated level of lactate dehydrogenase (LDH) and creatine 206 kinase were detected in 106 (40.0%) and 46 (17.4%) cases, respectively. The elevation of 207 erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) was common. 208 Compared with patients with mild and moderate COVID-19, those with severe or critically 209 210 disease presented with extensively and significantly different laboratory parameters, including lymphocytes and neutrophils, myocardial zymogram (creatine kinase, myoglobin, 211 212 troponin T, LDH, NT-proBNP), liver and renal function (alanine aminotransferase, aspartate

aminotransferase, albumin, serum creatine, and eGFR), coagulation function (activated
partial thromboplastin time, fibrin degradation products, and D-dimer), and infectionrelated biomarkers (CRP and procalcitonin). The counts of CD4+ and CD8+ cell of severe
or critically ill patients were 205/µl and 135/µl, significantly lower than those of the mild or
moderate patients (Figure 4).

218

#### 219 **Timeline and outcome of the disease progression**

220 The proportion of patients with mild, moderate, severe and critically ill diseases on 221 admission were 3.4% (9/265), 94.0% (249/265), 1.1% (3/265), and 1.5% (4/265), respectively. The spectrum of severity of diseases changed slightly as disease progressed. 222 Of the 9 mild cases without pulmonary abnormality on admission, 4 showed bilateral or 223 224 unilateral pneumonia in the subsequent chest CT tests which meant they were classified into moderate cases during hospitalization; and the remaining 5 had no changes in 225 226 pulmonary imaging follow-ups for more than two weeks. While all the 11 asymptomatic 227 patients had findings that consistent with pneumonia on routine CT examinations on 228 admission. One of the patients was asymptomatic until she was discharged 11 days after 229 being hospitalized. Two patients had subjective symptoms during the hospitalization. The 230 remaining patients were still under observation in the hospital and had no symptoms. The 231 median time for COVID-19 progressed to severe diseases was 8.5 days (IQR: 4.75-11.0 232 days), and to critically ill, requiring invasive mechanical ventilation, was 10.0 days (IQR: 233 5.5-11.0 days). There were 22 severely ill patients in the cohort, of which 21 were severely 234 ill within 14 days of the course of the disease (Figure 5). When reevaluated the patients

235	who were on day 14 of illness, we observed that 9.6% (17/177, 95%CI: 5.6-15.4%) had
236	severe or critically ill COVID-19 while 86.7% (152/177) were stable, and other 4.5% (8/177)
237	cured (Figure 6). By February 11 <sup>th</sup> , the proportion of patients being mile, moderate, sever
238	and critically ill were 1.9%(5/265), 89.8%(238/265), 3.8%(10/265), 4.5%(12/265),
239	respectively; 47 (17.7%) people in our cohort were discharged, and 1 (0.38%) patient died.
240	One of the critically ill patients was complicated with sepsis, two were treated with
241	continuous renal replacement therapies, three patients were on extra-corporeal membrane
242	oxygenation, and one patient recovered from severe disease to moderate condition.

243

### 244 Discussion

The first laboratory-confirmed case in Shanghai was reported in January 20th, and 245 246 epidemic of Shanghai has experienced an increasing trend, during which the amplification of the newly diagnosed cases per day was increasing continuously. However, the trend 247 had turned to a declining phase since January 31st. This phase was in accordance with the 248 249 most regions outside Hubei province in China. In Hubei, newly diagnosed cases were still increasing in Hubei and on Feb 12<sup>th</sup>, because the clinical diagnosis was included in the 250 251 guideline, the daily number of diagnosed patients had reached a spike of more than 10,000, allowing many suspected who haven't the chance to be laboratory-confirmed to be 252 253 admitted to the hospital for treatment. Therefore, in the near future, the local prevention 254 and control of COVID-19 in Hubei would enter into a critical stage, where a turning point 255 might be met if all measures were successively achieved.

256 Comparing the actual diseases trend in Shanghai with the previously estimated trends,

we could find out that Shanghai exhibited a high-efficiency epidemics controlling ability and 257 258 had stopped the exponential growth for now. The reason behind this is that during this 259 epidemic, Chinese and Shanghai government has issued very strong and strict measures in restricting the transmission in local regions. The national transport department 260 announced a 45% and 70.6% decline in the passenger flow at the beginning and the end 261 of 2020 Spring Festival, respectively [13-14]. What's more, Shanghai government 262 263 cancelled all gathering activities and through propaganda of the officials, media and community, citizens were well-informed and well-educated of the importance of wearing 264 face masks and washing hands frequently. Previous studies have suggested that the 265 266 mobility reduction could not effectively lower the incidence rate while 50% transmissibility 267 reduction could easily prevent the epidemics from further spreading [12]. In the case of 268 Shanghai, the transmissibility was indeed greatly reduced, however, we believe the 269 mobility reduction also played an indirect role in lowering the transmissibility. This is 270 because that Chinese Spring Festival is characterized by hundreds of millions of people 271 transporting from one region to another, and this massive gathering at the airports, train 272 stations during transportation, if not controlled, would significantly increase the human to 273 human transmission. Therefore, during this special period, controlling both mobility and 274 transmissibility might be important. Other doubt lies in that previous studies have reported 275 that the ascertainment rate in Wuhan is 5.1%[11], and suggested that other cities such as 276 Shanghai, Beijing have the similar ascertainment rate, which would lead to our local case 277 numbers fall below the true ones. However, in Shanghai for example, the suspected cases 278 were approximately 20 folds of the laboratory-confirmed cases. Thus we expected the

ascertainment rate outside Hubei province was closer to the actual epidemic size. But in the end, the disease prevention and control of the regions outside Hubei province would always heavily rely on the diminish of the epidemic in Hubei province, and the combination of Hubei epidemic control and strong measures to prevent local clustered cases outside Hubei will be the key to success.

In areas outside Hubei, the epidemics has transmitted from the first stage, in which 284 imported cases composed of the main laboratory-confirmed cases, to the second stage, 285 where imported cases and local sporadic or even clustered cases were simultaneously 286 287 seen while imported cases from Hubei province gradually reduced due to the region shut 288 down. In fact, clusters of cases within China and around the world without Hubei travelling 289 history have been reported, indicating the shifting of the epidemic characteristics globally. 290 In our study, we found that local cases increased approximately 5 days after the first the 291 imported cases, possibly due to the incubation period after these local cases were infected. 292 Also, the proportion of patients with a travel history to Hubei has gradually decreased, and 293 the proportion of patients without a travel history to in Hubei has gradually increased. This 294 suggests that strengthening prevention of local sporadic or clustered cases in areas outside Hubei in the future will be crucial for the second-stage epidemic control outside 295 296 Hubei province.

In our study, the incubation period is similar as other studies previously reported, but the mean onset-admission interval was 5.478 days, shorter than 12.5 day initially reported in Wuhan[15], suggesting the timely control and prevention of the diseases spreading. One reason behind this is the improvement of the diagnostic ability of the disease, mainly the

301 production of RT-PCR kit, which significantly shortened the diagnostic time frame.

302 The 11 asymptomatic patients in the Shanghai cohort were diagnosed after nucleic acid sampling of close contacts of confirmed patients. Routine chest CT examinations at 303 304 admission revealed pneumonia in all of them. Therefore, these patients can only be 305 considered asymptomatic but not in incubation. Although there was a reported case of incubation time up to 24 day [16], we believe that it is necessary to clarify whether an 306 307 imaging assessment was performed before the onset of symptoms in this patient. However, it is worth noting that, at the epidemiological level, these asymptomatic patients are almost 308 309 the same as those in the incubation period. A positive nasopharyngeal swab RT-PCR for 310 COVID-19 in these patients suggests that they do have the potential to infect others. We 311 therefore believe that more active inspections and evaluations of close contacts should be 312 undertaken.

313 The proportion of severe and critically ill patients in Shanghai was significantly lower than that in Wuhan. We consider the proportion of patients with severe illness to be a very 314 315 important indicator of the disease. First, regional mortality rate varies widely in the early 316 stages of the disease outbreak because it is affected by many factors, such as life support 317 equipment for critically ill patients and local medical conditions. In the absence of effective 318 antiviral drugs, the proportion of critically ill patients depicts the natural course of the 319 disease better than the mortality rate. Second, because the final clinical outcome of majority of the reported cases is typically unknown during a growing epidemic, dividing the 320 321 cumulative reported deaths by reported cases will underestimate the mortality rate early in 322 an epidemic[17]. We believe that the proportion of severe illness in Wuhan is biased

323 towards detecting severe cases, partly because diagnostic capacity is limited at the start 324 of an epidemic. Because of Shanghai's active surveillance, especially for suspected cases 325 with recent travel history to the affected region and close contacts, demonstrating by 326 shorter onset-administration interval and 4% asymptomatic patients on admission, 327 Shanghai should have picked up clinically milder cases as well as the more severe cases resulting a more reliable proportion of critically ill patients. To reduce the bias cause by mild 328 329 case in early stage, we calculated the proportion of critically ill patients among those with an onset of 14 days or more, since more than 95% sever cases in Shanghai developed 330 331 before that time. That proportion of 9.6% is substantially lower than SARS or MERS. The 332 early clinical manifestations of COVID-19 patients in Shanghai were similar to those 333 reported in Wuhan and elsewhere[7-9].

334 Our study showed relatively comprehensive laboratory test results in the published studies. Assessed through this systematic inspection, we can find that sever COVID-19 335 cases had extensive systemic laboratory abnormalities which indicated multisystem 336 337 involvement had existed before significant respiratory abnormalities appeared. Previous 338 studies have found that most patients had reduced lymphocytes and abnormal levels of many cytokines in critically ill patients [8,16]. Lymphocyte classification in our study showed 339 340 that CD4 and CD8 cells both decreased in COVID-19 patients, and ~15% patients had 341 CD4 / CD8 <1. This may be related to a systemic inflammatory response caused by a cytokine storm, which is similar to that of SARS patients. The severity classification of 342 343 COVID-19 patients in China mainly focuses on the respiratory system and oxygenation of patients. We believe more attention should be paid to other organs function of the patient 344

345	in addition to the respiratory system. As follow-up continues, we can observe the outcome
346	of more and more patients, and it should be possible to identify early risk factors that
347	indicate a poor prognosis.
348	Our study has several limitations. First, as the epidemics has not ended yet, the
349	effect of the control measures cannot be fully evaluated. Second, as most patients are
350	still hospitalized at the time of manuscript submission, clinical outcome remains to be
351	seen. Third, we did not measure cytokines and viral loads, which may be related to
352	disease progression and severity.
353	Conclusion
354	Strict measures on controlling disease transmissibility in a metropolis can quickly reduce
355	the spread of a new infectious diseases to polar levels and stop its exponential growth in
356	the short term. Controlling the local clusters is the key to prevent outbreaks due to imported
357	cases. Our studies showed that the incubation period for COVID-19 is $6.438$ days and $9.6\%$
358	of COVID-19 cases were severe cases. The median time for COVID-19 progressing to
359	severe diseases was 8.5 days and multiple systemic laboratory abnormalities which
360	indicated multisystem involvement had been observed before significant respiratory
361	abnormalities appeared.
362	
363	
364 265	Oral consent trom participate
366	Oral consent was obtained was obtained nom the patients.
367	Funding
368	This study was not funded.
369	
370	Competing interests
371	All authors declare no competing interests.

All rights reserved. No reuse allowed without permission.

### 372

## 373 Acknowledgements

We acknowledge all health-care workers involved in the diagnosis and treatment of patients and show the greatest appreciation to all health workers for their valuable input to the control of diseases.

- 377
- 378
- 379

### 380 Figure 1: COVID-19 trends in Shanghai

(A) Newly increased confirmed cases in Shanghai and the percentage of COVID-19 cases
 without travel history to Hubei Province. (B) Actual and predicted COVID-19 cases in
 Shanghai.



All rights reserved. No reuse allowed without permission.

# 394395 Figure 3. Key time-to-event distributions



396

397

398 399

### 400 Figure 4. Significantly different laboratory parameters

401 Compared to the mild-moderate cohort, some laboratory results were obviously abnormal in Severe-critically ill cohort, suggesting impairments in different system in severe or 402 critically ill COVID 2019 patients. Each box extends from the 25th to 75th percentiles, and 403 each whisker goes down to the smallest value and up to the largest value (except for 404 outliers. The shade between dotted line two dotted lines indicates the normal range of 405 parameters. (The whiskers were generated using Tukey method, where values were 406 regarded as outliers and not presented in this figure if greater than the sum of the 75<sup>th</sup> 407 percentile plus 1.5 IQR or less than 25<sup>th</sup> percentile minus 1.5IQR. Boxes, whiskers and 408 normal range change were extracted from graph of each parameter, adjusted to fit each 409 other in fixed proportions, the distribution of the testing results and their relationship with 410 normal range were not changed during the adjustment). All parameters presented in this 411 412 figure had significant difference between two cohorts (P<0.05).



413

414

415

All rights reserved. No reuse allowed without permission.

#### Figure 5. Days from illness onset to COVID-19 progression to severe illness. 417

- 418 x-axis: the observation time from the onset of symptom for each patient. d0 is defined as
- the date diagnosis of COVID-19 confirmed. 419



<sup>421</sup> 

422

#### Figure 6. The patient composition and classification of the cohort. 423

424 X-axis: the observation time from the onset of symptom for each patient. calculated; for

asymptomatic patients, d0 is defined as the date diagnosis of COVID-19 confirmed. 425



Y axis: the proportion of the entire cohort. 426

#### Table 1 Clinical symptoms, comorbidities, and radiology findings at admission 430

			Severe-critically	
	All Patients	Mild-moderate	ill	P value
	N=265	N=243	N=22	
Symptoms				
Fever	220 (90.9%)	200 (82.3%)	20 (90.9%)	0.303
Cough	131 (49.4%)	124 (51.0%)	7 (31.8%)	0.084
Expectoration	61 (23.0%)	55 (22.6%)	6 (27.3%)	0.621
Fatigue	67 (25.3%)	60 (24.7%)	7 (31.8%)	0.461
Inappetence	31 (11.7%)	28 (11.5%)	3 (13.6%)	0.730
Headache	26 (9.8%)	25 (10.3%)	1 (4.5%)	0.707
Myalgia	23 (8.7%)	21 (8.6%)	2 (9.1%)	0.999
Chest tightness	12 (4.5%)	9 (3.7%)	3 (13.6%)	0.067
Chest pain	6 (2.3%)	5 (2.1%)	1 (4.5%)	0.409
Dyspnea	5 (1.9%)	1 (0.4%)	4 (18.2%)	<0.0001
Rhinorrhea	16 (6.0%)	16 (6.6%)	0 (0.0%)	0.376
Sore throat	12 (4.5%)	12 (4.9%)	0 (0.0%)	0.607
Diarrhea	17 (6.4%)	17 (7.0%)	0 (0.0%)	0.200
Nausea or vomiting	6 (2.3%)	6 (2.5%)	0 (0.0%)	0.999
Comorbidities				
Hypertension	52 (19.6%)	42 (17.3%)	10 (45.5%)	0.004
<b>Diabetes Mellites</b>	21 (7.9%)	15 (6.2%)	6 (27.3%)	0.004
Coronary diseases	14 (5.3%)	10 (4.1%)	4 (18.2%)	0.021
COPD	4 (1.5%)	2 (0.8%)	2 (9.1%)	0.036
Tumor	6 (2.3%)	5 (2.1%)	1 (4.5%)	0.409
Chronic renal diseases	5 (1.9%)	3 (1.2%)	2 (9.1%)	0.057
Hyperlipidemia	4 (1.5%)	4 (1.6%)	0 (0.0%)	0.999
Cerebrovascular	2(0.99/)	1 (0 40/)	1 (1 50/)	0 150
diseases	2 (0.0%)	1 (0.4%)	1 (4.5%)	0.159
Autoimmune diseases	2 (0.8%)	1 (0.4%)	1 (4.5%)	0.159
Chronic liver diseases	1 (0.4%)	0 (0.0%)	1 (4.5%)	0.083
Radiology manifestation	n			0.263
Normal	9 (3.4%)	9 (3.7%)	0 (0.0%)	
Unilateral involved	51 (19.2%)	49 (20.2%)	2 (9.1%)	
Bilateral involved	205 (77.4%)	185 (76.1%)	20 (90.9%)	

Data were shown as n (%). 431

Abbreviation: COPD, chronic obstructive pulmonary disease 432

#### Table 2 Laboratory examination at admission 434

	All Detients	Mild-moderate	Severe-critically	
	All Patients		ill	P value
	N=205	N=243	N=22	
Blood routine an	nd lymphocyte clas	ssification		
WBC	4.6 (3.8-5.9)	4.7 (3.9-5.7)	4.5 (3.8-6.9)	0.556
Lymphocytes	1.1 (0.8-1.5)	1.2 (0.9-1.5)	0.7 (0.5-1.0)	<0.0001
Neutrophils	2.9 (2.3-3.9)	2.8 (2.3-3.8)	3.3 (2.7-4.8)	0.033
Hemoglobin	136.1 (18.01)	135 (125-148)	145 (123-151)	0.221
Platelets	176 (141-219)	177 (142-219)	156 (122-211)	0.37
CD8 cell	260 (164-396)	266 (176 -411)	135 (76-230)	<0.0001
CD4 cell	431 (300-650)	455 (312-652)	205 (115-354)	<0.0001
Blood biochemis	stry			
ALT	23.0 (15.0-33.0)	21.0 (15.0-33.0)	30.0 (24.5-34.5)	0.012
AST	24.0 (19.0-33.0)	24.0 (19.0-31.0)	39.5 (29.7-53.5)	<0.0001
Total bilirubin	7.90 (6.5-10.5)	7.80 (6.4-10.3)	8.9 (7.3-13.3)	0.05
Albumin	40.8 (37.8-43.0)	41.0 (37.8-43.4)	36.8 (33.0-39.4)	<0.0001
NT-proBNP	34.6 (23.0-67.6)	32.90 (22.4-61.0)	76.1 (37.7-694.0)	<0.0001
Myoglobin	6.7 (3.1-15.3)	5.73 (2.8-12.4)	34.5 (19.2-174.3)	<0.0001
Troponin T	0.02 (0.01-0.04)	0.02 (0.01-0.04)	0.04 (0.02-0.09)	<0.0001
	222 (105 202)	228.0 (192.5-	254 (204 466)	-0.0001
LDH	232 (195-293)	276.0)	334 (304-400)	<0.0001
Creatine kinase	83 (56-133)	7 (550-121)	226 (110-443)	<0.0001
Serum	63 6 (52 4-76 1)	63 0 (51 8-75 2)	72 8 (57 3-05 8)	0.008
Creatine	05.0 (52.4-70.1)	03.0 (31.0-73.2)	72.0 (37.3-93.0)	0.000
eGFR	110 (96-127)	112 (97-129)	99.8 (73.8-118.8)	0.016
Lactic acid	2.74 (2.33-3.21)	2.7 (2.3-3.2)	2.9 (2.4-3.6)	0.254
Potassium	3.80 (3.60-4.00)	3.8 (3.5-4.0)	3.9 (3.6-4.1)	0.206
Sodium	139 (137-141)	139 (138-141)	136 (131-139)	<0.0001
Coagulation fun	ction			
PT	13.3 (13.00-13.)	13.3 (13.0-13.8)	13.5 (12.9-14.1)	0.266
APTT	39.5 (36.3-42.6)	39.3 (36.3-42.0)	41.9 (36.8-49.3)	0.027
FDP	0.92 (0.42-1.76)	0.85 (0.35-1.54)	1.9 (1.2-3.1)	<0.0001
D-dimer	0.42 (0.29-0.80)	0.39 (0.28-0.72)	0.8 (0.5-3.5)	<0.0001
Infection-related parameters				
Procalcitonin	0.03 (0.02-0.06)	0.03 (0.02-0.05)	0.08 (0.05-0.15)	<0.0001
CRP	9.8 (2.5-27.4)	8.6 (1.9-23.5)	53.5 (20.5-96.1)	<0.0001
ESR	50.5 (29.0-90.0)	49.0 (27.2-90.0)	52.0 (38.7-91.5)	0.473

Data are shown as median value (interquartile range). 435

Abbreviation: WBC, white blood cell; ALT, alanine aminotransferase; AST, aspartate 436 aminotransferase; NT-proBNP, N-terminal pro-B-type natriuretic peptide; LDH, lactate 437 dehydrogenase; eGFR, estimated glomerular filtration rate; PT, prothrombin time; APTT, 438 Activated partial thromboplastin time; FDP, Fibrinogen degradation products; CRP, c-439

reactive protein; ESR, erythrocyte sedimentation rate. 440

medRxiv preprint doi: https://doi.org/10.1101/2020.02.19.20025031; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

#### 441 References:

- J. C. Chinese researchers reveal draft genome of virus implicated in Wuhan pneumonia 442 1. outbreak. In. Washington, DC: American Association for the Advancement of Science 443 https://www.sciencemag.org/news/2020/01/chinese-researchers-reveal-draft-444 445 genome-virus-implicated-wuhan-pneumonia-outbreak.
- 446 2. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in
- China, 2019. N Engl J Med. 2020:10.1056/NEJMoa2001017. 447
- WHO names deadly virus from China as 'COVID-19'. In. https://guardian.ng/news/who-448 3. 449 names-deadly-virus-from-china-as-covid-19/.
- 450 4. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the 451 United States. N Engl J Med. 2020:10.1056/NEJMoa2001191.
- Kim JY, Choe PG, Oh Y, et al. The First Case of 2019 Novel Coronavirus Pneumonia 452 5. 453 Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures. J Korean Med Sci. 2020;35(5):e61-e61. 454
- 6. Coronavirus diseases 2019 (COVID-19) 455 Situation Report-28 https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200217-456 457 sitrep-28-covid-19.pdf?sfvrsn=a19cf2ad 2
- 458 7 Wang D, Hu B, Hu C et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020 Feb 07.\ 459
- Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel 460 8. coronavirus in Wuhan, China. Lancet 2020 Feb 15;395(10223). 461
- Zhang YP et al. Analysis of Epidemiological Characteristics of New Coronavirus 462 9. 463 Pneumonia. Chin J Epidemiol, February 2020, Vol 41, No.2. (Chinese)
- 10. World Health Organization. Clinical management of severe acute respiratory infection 464 when Novel coronavirus (nCoV) infection is suspected: interim guidance. In. 465 https://www.who.int/internal-publications-detail/clinical-management-of-severe-acute-466 respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. 467
- Read J, Bridgen J, Cummings D et al. Novel coronavirus 2019-nCoV: early estimation 468 11. 469 of epidemiological parameters and epidemic predictions. Doi: . 470 http://dx.doi.org/10.1101/2020.01.23.20018549
- 12. Wu JT, Leung K, Leung GM et al. Nowcasting and forecasting the potential domestic 471 472 and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet 2020 Jan 31. 473
- 474 13 Epidemics prevention conference
- http://shanghai.xinmin.cn/xmsq/2020/02/15/31659664.html (accessed Feb 18<sup>th</sup> 2020) 475
- http://www.zgitb.com/2020-02/09/content 234857.htm (accessed Feb 18<sup>th</sup> 2020) 476 14.
- Li Q, Guan X, Wu P et al. Early Transmission Dynamics in Wuhan, China, of Novel 477 15. Coronavirus-Infected Pneumonia. N. Engl. J. Med. 2020 Jan 29. 478
- Guan W, Ni Z, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection 479 16. 480 in China[J]. medRxiv, 2020:2020-2022.
- 481 17. Garske T, Legrand J, Donnelly C A, et al. Assessing the severity of the novel influenza 482 A/H1N1 pandemic[J]. Bmj, 2009,339:b2840.